Hls Therapeutics, Inc. · TSX:HLS
Hls Therapeutics — Q4 2025 Earnings Presentation
20 slides from Hls Therapeutics's earnings presentation, Mar 12, 2026
Slide 1: Fiscal 2025 Conference Call
Fiscal 2025 Conference Call March 12, 2026 Craig Millian, CEO John Hanna, CFO Brian Walsh, CCO TSX - HLS
Slide 2: Forward-Looking Statements
Forward-Looking Statements Certain statements in this presentation are “forward-looking statements”. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions or future events or performance (often, but not alwa
Slide 3: Track Record of Growing Profitability and Cash Flow
Track Record of Growing Profitability and Cash Flow Adj. EBITDA Cash from Operations Net Debt ($000’s) ($000’s) ($000’s) 20,000 18,000 50,000 18,000 45,000 16,000 16,000 40,000 14,000 14,000 35,000 12,000 12,000 30,000 10,000 10,000 18% 8,000 114% 25,000 23% 8,000 20,000 6,000 6,000 15,000 4,000 4,0
Slide 4: Three Products, One Goal: Reducing CV Risk for More Canadians
Three Products, One Goal: Reducing CV Risk for More Canadians VASCEPA NILEMDO NEXLIZET Building a leading CV portfolio in Canada Toronto Stock Exchange (TSX) - HLS Provided as part of an oral presentation and qualified by such, contains forward-looking statements, actual results may vary materially;
Slide 5: Why We’re Excited About the NILEMDO/NEXLIZET Opportunity
Why We’re Excited About the NILEMDO/NEXLIZET Opportunity Large Strong Compelling Solid Multiple addressable clinical value economics catalysts next market data proposition 18-24 months Potential to more than double the size of Cardiovascular business Toronto Stock Exchange (TSX) - HLS Provided as pa
Slide 6: Strong Financial Position Unlocks Value Creation Opportunities
Strong Financial Position Unlocks Value Creation Opportunities BD CRITERIA: Balanced approach to Commercial-stage, licensable assets capital allocation with Strategic organizational fit the priority of pursuing Meaningful sales potential BD opportunities Disciplined financial framework Toronto Stock
Slide 7: 2026 Guidance
2026 Guidance Revenue Adj EBITDA $56-60M $18.5-21M 2026: Building momentum. 2027: Accelerating growth Toronto Stock Exchange (TSX) - HLS Provided as part of an oral presentation and qualified by such, contains forward-looking statements, actual results may vary materially; HLS disclaims any duty to
Slide 8: Life-changing medicine for Treatment Resistant Schizophrenia
Life-changing medicine for Treatment Resistant Schizophrenia Toronto Stock Exchange (TSX) - HLS Provided as part of an oral presentation and qualified by such, contains forward-looking statements, actual results may vary materially; HLS disclaims any duty to update
Slide 9: Building a Canadian leader in oral cardiovascular risk reduction
Building a Canadian leader in oral cardiovascular risk reduction Toronto Stock Exchange (TSX) - HLS Provided as part of an oral presentation and qualified by such, contains forward-looking statements, actual results may vary materially; HLS disclaims any duty to update
Slide 10: Continued Prescribing Growth
Continued Prescribing Growth TRx Units Since Launch 180000 160000 23% increase in unit demand* 140000 120000 100000 31% increase in consistent prescribers* 80000 60000 40000 Strengthening new-to-brand momentum 20000 0 2020 2021 2022 2023 2024 2025 *Compared to fiscal 2024 Vascepa contributed $1M to
Slide 11: NILEMDO & NEXLIZET: CV Franchise Expansion
NILEMDO & NEXLIZET: CV Franchise Expansion NILEMDO: Bempedoic acid monotherapy CDA (ex-CADTH) submission completed Oral LDL lowering medicine Health Canada approved November 2025 KOL engagement programs launched Product available March 2026 Sales force training and readiness NEXLIZET: Combination th
Slide 12: Benefits of a Staged Launch: Multiple Near-Term Catalysts
Benefits of a Staged Launch: Multiple Near-Term Catalysts NEXLIZET Initial approval & Private public PLAs launch NILEMDO payer expected Q1/Q2 2027 promotion listings Q1 2027 NILEMDO launch Q2/Q3 2026 Available Q2 2026 Q1 2026 Long patent runway: Vascepa to 2039, NILEMDO/NEXLIZET to 2040 Toronto Stoc
Slide 13: Financial Review: Strengthening Foundation to Support Growth
Financial Review: Strengthening Foundation to Support Growth Toronto Stock Exchange (TSX) - HLS Provided as part of an oral presentation and qualified by such, contains forward-looking statements, actual results may vary materially; HLS disclaims any duty to update
Slide 14: Revenue Growth from Marketed Products
Revenue Growth from Marketed Products 1% growth in marketed products, excluding royalties and f/x impact 1.5% growth in Canadian marketed products in local currency 1.6% decline in US sales of Clozaril Improvement from four-year average annual decline of 6% Toronto Stock Exchange (TSX) - HLS Provide
Slide 15: Reducing Expenses, Improving Margins & Generating Cash Flow
Reducing Expenses, Improving Margins & Generating Cash Flow Operating Expenses Adjusted EBITDA Cash from Operations (excluding Cost of Sales) ($000’s) ($000’s) ($000’s) 35,000 20,000 18,000 16,000 30,000 14,000 15,000 25,000 12,000 20,000 10,000 17% 10,000 18% 8,000 114% 15,000 6,000 10,000 5,000 4,
Slide 16: Operational Changes Delivering Improved Profitability
Operational Changes Delivering Improved Profitability Adjusted EBITDA ex Royalties (trailing twelve month basis) 20000 18000 16000 14000 12000 $(000s) 10000 88% 8000 6000 4000 2000 0 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Toronto Stock Exchange (TSX) - HLS Pr
Slide 17: Expect Quarterly Seasonality to Continue in 2026
Expect Quarterly Seasonality to Continue in 2026 Adjusted EBITDA by Quarter (2024-2025) 7.0 6.0 5.7 5.6 5.2 5.0 4.9 4.3 $(millions) USD 4.1 4.0 3.8 3.0 2.7 2.0 1.0 0.0 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Toronto Stock Exchange (TSX) - HLS Provided as part of an oral prese
Slide 18: De-levering and Strengthening the Balance Sheet
De-levering and Strengthening the Balance Sheet Summary Balance Sheet & Capitalization Net Debt (US$ millions) 80 (US$ millions) At Dec 31, 2024 At Dec 31, 2025 70 Cash and Cash Equivalents 17.5 11.7 1 60 Senior Secured Term Loan 67.4 50.0 50 Net Debt (Term Loan less Cash) 50.0 38.3 40 49% 30 20 At
Slide 19: Summary
Summary 1 Consistent Profitability (Adj. EBITDA) Growth: 18% YoY, 88%* since Q3 2023 2 Strong Cash Generation: cash from operations up 114% YoY 3 Vascepa Profitability Achieved: first full-year positive Adj. EBITDA contribution 4 Growth Catalyst in Place: NILEMDO now available; commercial launch Apr
Slide 20: Fiscal 2025 Conference Call
Fiscal 2025 Conference Call March 12, 2026 Craig Millian, CEO John Hanna, CFO Brian Walsh, CCO TSX - HLS